Candel Therapeutics, Inc. (CADL) stock forecast and price target
Price $6.20 · data as of November 13, 2026
12-month price target
Average target$17.67
Upside / downside+184.9%
Analysts9
ConsensusStrong buy
Low $11.00Average $17.67High $29.00
Gold marker: average target · white marker: today’s price ($6.20)
Analyst ratings
Strong buy 0Buy 10Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-1.18 | −34.7% | $0 |
| Next fiscal year ends December 31, 2027 | $-1.44 | −21.6% | $10M |
| Next quarter ends December 31, 2026 | $-0.30 | −4.8% | $0 |
| Quarter after ends March 31, 2027 | $-0.34 | — | $0 |
Consensus of the analysts covering Candel Therapeutics, updated daily. In the last 30 days 0 estimates were raised and 1 lowered.
Frequently asked questions
What is the Candel Therapeutics stock price target?
The average 12-month target from 9 analysts is $17.67, 184.9% above the current price of $6.20 Targets range from $11.00 to $29.00.
Is Candel Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (10 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Candel Therapeutics expected to earn?
Analysts expect EPS of $-1.18 for the fiscal year ending December 31, 2026 and $-1.44 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.